In conclusion, DDX39B acts as a tumor promoter in CRC by upregulating the expression of FUT3 and then promoting the fucosylation of TGFβR-I, which subsequently enhances activation of the TGFβ/SMAD2 signaling pathway to facilitate the invasion and metastasis of CRC. Here, SMAD2 is linked to neoplasm.